Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

pical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future eve
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
(Date:6/19/2013)... 19, 2013 Bayer CropScience will honor ... Bee Care Community Leadership Award. The award will be ... Reception in Washington, D.C., an event where supporters of ... world’s food supply. , The Bayer Bee Care ... power of the honey bee colony to benefit their ...
(Date:6/19/2013)... ANGELES , June 19, 2013 Biotechnology industry ... teaming up with financial software provider BlackLine Systems ... SAP ) for a webinar next week entitled ... Uses Solutions from BlackLine and SAP to Help Keep Its ... (Logo: http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared ...
(Date:6/19/2013)... 19, 2013 BioConvergence team members ... faculty at 2013’s BioLogistics Summit in San Francisco ... by Cold Chain IQ and IQPC, addressed the ... is, in part, attributed to current trends of ... within these trends is an increase in movement, ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2
... GPRO ) announced today that the Company will present ... Tuesday, November 18,2008 at approximately 3:10 p.m. Eastern Time. ... be accessed through a link on the investors,section of ... available for 30 days following the event., About ...
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... PharmAthene, Inc.,(NYSE Alternext US: PIP), a biodefense company ... reported,financial and operational results for the third quarter ... the third quarter of 2008, PharmAthene recognized revenues ... same period of 2007. For the nine,months ended ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7
(Date:6/18/2013)... Laboratory of Molecular Biology, has been honored as ... Award. Torrent is being recognized for his outstanding ... predict antimicrobial regions in proteins. Luis Rivas, Centro ... this algorithm to interrogate full genomes in order ... appealing results." , Torrent obtained his Ph.D. ...
(Date:6/18/2013)... estimated that between 5% and 10% of breast and ... say that these tumours are attributable to inherited mutations ... BRCA2. In patients with these mutations, PARP inhibitors, which ... that make them a new option for personalised cancer ... studies indicate that a fraction of these patients generate ...
(Date:6/17/2013)... nervous system infections may well be suffering from the ... study to be published in mBio , the ... Researchers have detected the virus in spinal fluid from ... infections of unknown cause, and in an average of ... suggesting animals may serve as reservoirs for transmission to ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... global study has found all forms of tobacco exposure, whether ... the risk of heart attack. , The study by professors ... School of Medicine at McMaster University and Hamilton Health Sciences ... Lancet. , In collaboration with colleagues from 52 countries, they ...
... have found that years after experiencing childhood polio, ... expected in their elderly counterparts, but rather experience ... with normal aging. , "Other researchers have suggested ... in life, but we've actually found it to ...
... South African scientists working at the epicenter of the ... human immunodeficiency virus (HIV) "exhausts" killer T cells that ... HIV can simply "turn off" fully functional T cells ... test tube studies, however, the scientists showed that they ...
Cached Biology News:Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3Survivors of childhood polio do well decades later as they age 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... Double staining is a technique used to ... tissue.(1-6) PicTure™-Double Staining Kit is a Zymed ... two antigens simultaneously in the same human ... The antigens can be identified using two ...
... exciting product for cell-based kinetic assays and ... use of expensive HTS equipment, which lead ... assay development stage. The NOVOstar offers the ... well as any other assay suitable for ...
Biology Products: